alpha-2-macroglobulin like 1Genealiases: CPAMD9 · OMS · p170
Q-omics provides the consensus-scored A2ML1 profile across patient tissues and cancer cell-line models. A2ML1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, A2ML1 is differentially expressed in 9, with the highest sampling consensus in LUSC. Additionally, A2ML1 RNA expression shows 14,618 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUSC, and TGCT as cancer lineages where A2ML1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for A2ML1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes A2ML1 survival associations across molecular data types. A2ML1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible A2ML1 RNA expression–survival associations across cancer types. High A2ML1 expression shows unfavorable associations in KIRC, KICH, LUAD, BRCA and SKCM, but favorable associations in LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for A2ML1 RNA expression.
This table summarizes A2ML1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in LUSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for A2ML1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. A2ML1 shows lower tumor expression in HNSC and THCA and higher tumor expression in LUSC, BLCA, BRCA and LUAD. The LUSC box plot shows higher A2ML1 RNA expression in tumor versus normal tissue (log2 FC = +4.924, t-test p < 0.001).
This table shows molecular features associated with A2ML1 in patient tissues and cancer cell lines. In patient samples, A2ML1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, A2ML1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
